Prokidney (PROK) Free Cash Flow (2021 - 2026)
Prokidney's (PROK) quarterly Free Cash Flow came in at -$44.2 million in Q2 2026, down 28.03% year-over-year from -$61.4 million in Q2 2025, and up 2.78% quarter-over-quarter from -$45.5 million in Q1 2026.
Analysis
Prokidney (PROK) Free Cash Flow (2021 - 2026) Analysis & Trends
Prokidney (PROK) has reported Free Cash Flow for 6 consecutive years, with -$44.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Free Cash Flow fell 28.03% year-over-year to -$44.2 million in Q2 2026; TTM through Jun 2026 was -$159.7 million, a 8.97% decrease from a year earlier, with the FY2025 full-year figure at -$135.3 million, up 13.18% from the prior year.
- Free Cash Flow was -$44.2 million for Q2 2026 at Prokidney, up from -$45.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$16.1 million in Q4 2022 and troughed at -$51.7 million in Q3 2023.
- A 5-year average of -$32.4 million and a median of -$31.7 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 11810044.93% in 2022 and soared 38.81% in 2024, its largest moves.
- Over 5 years, Free Cash Flow stood at -$16.1 million in 2022, then tumbled by 67.77% to -$27.0 million in 2023, then plunged by 84.3% to -$49.7 million in 2024, then grew by 22.98% to -$38.3 million in 2025, then retreated by 15.53% to -$44.2 million in 2026.
- The last three Free Cash Flow figures came in at -$44.2 million (Q2 2026), -$45.5 million (Q1 2026), and -$38.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 71.22 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -84.15 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -66.26 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -13.40 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -29.05 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -68.51 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | -18.20 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 196.52 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 14.46 Mn |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | -44.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44.21 Mn |
| Mar 31, 2026 | -45.47 Mn |
| Dec 31, 2025 | -38.27 Mn |
| Sep 30, 2025 | -31.79 Mn |
| Jun 30, 2025 | -34.53 Mn |
| Mar 31, 2025 | -30.73 Mn |
| Dec 31, 2024 | -49.68 Mn |
| Sep 30, 2024 | -31.65 Mn |
| Jun 30, 2024 | -38.93 Mn |
| Mar 31, 2024 | -35.61 Mn |
| Dec 31, 2023 | -26.96 Mn |
| Sep 30, 2023 | -51.72 Mn |
| Jun 30, 2023 | -18.62 Mn |
| Mar 31, 2023 | -26.98 Mn |
| Dec 31, 2022 | -16.07 Mn |
| Sep 30, 2022 | -23.16 Mn |
| Jun 30, 2022 | -23.41 Mn |
| Mar 31, 2022 | -16.30 Mn |
| Dec 31, 2021 | -1.75 Mn |
| Sep 30, 2021 | -1.14 Mn |